Given the continued performance of these initiatives, we’ve decided to increase our guidance for fiscal 2012, for the second time this year. Revenue is now expected to be in the range of $492 million to $496 million, which represents 22% to 23% growth over the prior fiscal year. Diluted earnings per share guidance has also been increased to $1.29 to $1.31 representing a 17% to 19% growth over fiscal 2011.These strong results have positioned us well for continued success, particularly when combined with the strategic directives that we are focusing on for long term growth. Myriad is dedicated to improving patient care through the development and marketing of transformative tests across multiple medical specialties, which do have present clinical needs. With this strategy in mind we’ve put forward the following three strategic directives. One to grow existing tests and markets, two to expand our business internationally, and three to launch new transformative products including companion diagnostic tests across a diverse set of major disease indications.
Myriad Genetics' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.